When was Etrasimod-Velsipity launched?

Etrasimod (Etrasimod), as an innovative oral S1P receptor modulator, was officially approved by the U.S. Food and Drug Administration (FDA) in October 2023 and was the first to be launched on the U.S. market. This time point is of milestone significance for the treatment of ulcerative colitis(UC), because the previous long-term dependence treatments were mainly glucocorticoids, immunosuppressants, and biological agents, and some patients had problems with insufficient response, poor tolerance, or long-term dependence. The emergence of itrimod has opened up a new situation for oral small molecule targeted drugs in the field of UC treatment.

From the perspective of the research and development process,Etrasimod was originally developed by Arena Pharmaceuticals. In 2022, Pfizer completed the acquisition of Arena, thus taking over the subsequent research and development and commercialization of the drug. Pfizer relied on its global market channels and R&D resources to accelerate the drug review process, ultimately allowing the drug to be successfully approved in the fall of 2023. The FDA's time to market not only means that American patients can benefit first, but also promotes its review progress in Europe and other regions.

For the European market, Itramod has also received positive opinions from the European Medicines Agency (EMA) in early 2024 and will gradually launch marketing in some countries. This shows that the drug's application prospects have been recognized by major regulatory agencies around the world. In the Chinese market, itramod is not yet available on the market. Formal review and approval has not yet been initiated in China, so patients will still need to obtain it through overseas channels in the short term.

Generally speaking, the launch time of itridimod is very consistent with the global trend of high incidence of inflammatory bowel disease. Its FDA approval in October 2023 not only enhances the status of oral small molecule drugs in the field of UC treatment, but also marks the gradual transition of immune disease treatment from traditional regimens to more precise and convenient targeted therapies.

Reference materials:https://www.drugs.com/mtm/etrasimod.html